Selexipag
Brand name: Uptravi
Rank #67 of 500 drugs by total cost
$279.1M
Total Cost
12,320
Total Claims
$279.1M
Total Cost
335
Prescribers
$23K
Cost per Claim
496
Beneficiaries
12,473
30-Day Fills
$833K
Avg Cost/Provider
37
Avg Claims/Provider
About Selexipag
Selexipag (sold as Uptravi) was prescribed 12,320 times by 335 Medicare Part D providers in 2023, costing the program $279.1M. At $23K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 64 | Bimatoprost (Lumigan) | $284.4M | 610,243 |
| 65 | Apremilast (Otezla) | $283.9M | 59,020 |
| 66 | Budesonide/Glycopyr/Formoterol (Breztri Aerosphere) | $280.9M | 340,138 |
| 67 | Selexipag (Uptravi) | $279.1M | 12,320 |
| 68 | Liraglutide (Victoza 3-Pak) | $273.0M | 189,358 |
| 69 | Elexacaftor/Tezacaftor/Ivacaft (Trikafta) | $269.3M | 9,821 |
| 70 | Immune Globul G/Gly/Iga Avg 46 (Gamunex-C) | $266.5M | 27,501 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology